This study detected the tumor-specific mutations through next-generation sequencing, synthesized neoantigen mRNA in vitro, made a dendritic cell (DC) vaccine directed at neoantigen and used haploidentical T cells activated by DC vaccine as effector cells to treat a refractory angioimmunoblastic T-cell lymphoma (AITL).A 72-yr-old man, with 1 mo of systemic lymphadenopathy, was admitted to the hospital on March 24, 2017, and phys. examination showed multiple lymphadenectasis at neck, bilateral axillas and inguens.Next-generation sequencing of circulating tumor DNA (ctDNA) showed mutations in gene RHOA, TET2, DNMT3A, NOTCH1, MEF2B.They used the DCs transfected with neoantigen mRNA to stimulate haploidentical T cell to treat a refractory AITL for T cells from healthy donor have normal functions and may contain less regulatory T cells than T cells from the tumor.The results suggests that neoantigen-activated haploidentical T cell therapy can be effective in controlling T-cell lymphoma.